# Janagliflozin Treat T2DM Monotherapy

> **NCT03811548** · PHASE3 · UNKNOWN · sponsor: **Sihuan Pharmaceutical Holdings Group Ltd.** · enrollment: 442 (estimated)

## Conditions studied

- Diabetes Type 2

## Interventions

- **DRUG:** Janagliflozin 25mg
- **DRUG:** Janagliflozin 50mg
- **DRUG:** Placebo/Janagliflozin

## Key facts

- **NCT ID:** NCT03811548
- **Lead sponsor:** Sihuan Pharmaceutical Holdings Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-23
- **Primary completion:** 2020-06-24
- **Final completion:** 2020-12-31
- **Target enrollment:** 442 (ESTIMATED)
- **Last updated:** 2020-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811548, "Janagliflozin Treat T2DM Monotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03811548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*